Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 5kWORD 18k
19 November 2018
Question for written answer E-005827-18
to the Commission
Rule 130
Ernest Urtasun (Verts/ALE)

 Subject:  Drug cost sharing
 Answer in writing 

In 2012, the Spanish Government introduced a system of drug cost sharing (Royal Decree-Law 16/2012) which increased the amount patients have to pay for medicines.

A recent study revealed that this system has exacerbated inequality in the health system, affecting low-income households, pensioners and the chronically ill. As a result, patients have stopped taking the medicines prescribed by their doctors as they simply cannot afford them: the number of patients not picking up prescriptions has risen by more than 50%.

In the light of the negative impact of the drug cost-sharing system on the Spanish population, particularly on the most vulnerable:
1. Does the Commission believe that this system violates Articles 34 and 35 of the Charter of Fundamental Rights of the European Union, which guarantee health protection and a decent existence?
2. Does the Commission believe that this system is compatible with the commitments made in the European Pillar of Social Rights, which, for example, protects equal opportunities and the right to healthcare (key principles 3 and 16)?
3. What measures will the Commission take to guarantee fair and equal access to drugs and healthcare?
Original language of question: ES 
Last updated: 4 December 2018Legal notice